Q-omics provides the consensus-scored SDHAF4 profile across patient tissues and cancer cell-line models. SDHAF4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, SDHAF4 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, SDHAF4 RNA expression shows 17,958 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, KICH, and UVM as cancer lineages where SDHAF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDHAF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDHAF4 survival associations across molecular data types. SDHAF4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDHAF4 RNA expression–survival associations across cancer types. High SDHAF4 expression shows unfavorable associations in SCLC and THCA, but favorable associations in SKCM, THYM, KIRC and OV. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for SDHAF4 RNA expression.
This table summarizes SDHAF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SDHAF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDHAF4 shows lower tumor expression in KICH, BRCA and KIRC and higher tumor expression in LIHC, COAD and CHOL. The KICH box plot shows higher SDHAF4 RNA expression in normal versus tumor tissue (log2 FC = −1.462, t-test p < 0.001).
This table shows molecular features associated with SDHAF4 in patient tissues and cancer cell lines. In patient samples, SDHAF4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SDHAF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
